[go: up one dir, main page]

MX2009008518A - Compuestos y composiciones como inhibidores de la proteasa activadora de canal. - Google Patents

Compuestos y composiciones como inhibidores de la proteasa activadora de canal.

Info

Publication number
MX2009008518A
MX2009008518A MX2009008518A MX2009008518A MX2009008518A MX 2009008518 A MX2009008518 A MX 2009008518A MX 2009008518 A MX2009008518 A MX 2009008518A MX 2009008518 A MX2009008518 A MX 2009008518A MX 2009008518 A MX2009008518 A MX 2009008518A
Authority
MX
Mexico
Prior art keywords
compounds
channel activating
compositions
protease inhibitors
activating protease
Prior art date
Application number
MX2009008518A
Other languages
English (en)
Inventor
David C Tully
Zhiwei Wang
Arnab K Chatterjee
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MX2009008518A publication Critical patent/MX2009008518A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La invención proporciona compuestos y composiciones farmacéuticas de los mismos, los cuales son útiles para modular las proteasas activadoras de canal, y métodos para utilizar tales compuestos con el fin de tratar, disminuir, o prevenir una condición asociada con una proteasa activadora de canal, íncluyendo, pero no limitándose a prostasina, PRSS22, TMPRSS11 (por ejemplo, TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptasa (MTSP-1), CAP2, CAP3, tripsina, catepsina A, o elastasa de neutrófilos.
MX2009008518A 2007-02-09 2008-01-07 Compuestos y composiciones como inhibidores de la proteasa activadora de canal. MX2009008518A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88901807P 2007-02-09 2007-02-09
PCT/US2008/050403 WO2008097676A1 (en) 2007-02-09 2008-01-07 Compounds and compositions as channel activating protease inhibitors

Publications (1)

Publication Number Publication Date
MX2009008518A true MX2009008518A (es) 2009-08-20

Family

ID=39323929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008518A MX2009008518A (es) 2007-02-09 2008-01-07 Compuestos y composiciones como inhibidores de la proteasa activadora de canal.

Country Status (11)

Country Link
US (1) US8293915B2 (es)
EP (1) EP2117537A1 (es)
JP (1) JP2010518099A (es)
KR (1) KR20090108131A (es)
CN (1) CN101600428A (es)
AU (1) AU2008214217B2 (es)
BR (1) BRPI0807483A2 (es)
CA (1) CA2677487A1 (es)
EA (1) EA016327B1 (es)
MX (1) MX2009008518A (es)
WO (1) WO2008097676A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101069051B1 (ko) 2006-05-23 2011-09-29 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
EP2117537A1 (en) 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2432556A1 (en) 2009-05-18 2012-03-28 Orion Corporation Protease inhibitors
CN103827098B (zh) * 2011-07-26 2016-06-15 赛诺菲 取代的3-(噻唑-4-羰基)-或者3-(噻唑-2-羰基)-氨基丙酸衍生物及其作为药物的用途
KR20140102253A (ko) * 2011-11-25 2014-08-21 에프. 호프만-라 로슈 아게 카텝신의 억제제로서의 피롤리딘 유도체
US10399940B2 (en) * 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JP7692353B2 (ja) 2018-10-02 2025-06-13 ディスク・メディスン，インコーポレイテッド マトリプターゼ２阻害剤及びその使用
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
BR112022004861A2 (pt) 2019-09-17 2022-06-07 Univ Duke Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro
FI4106757T3 (fi) 2020-04-16 2023-10-23 Mereo Biopharma 4 Ltd Neutrofiilien elastaasin inhibiittori alvelestaattia sisältäviä menetelmiä alfa-1-antitrypsiinipuutoksen välittämän hengityselintaudin hoitamiseksi
US20240382472A1 (en) 2021-10-20 2024-11-21 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809316D0 (en) 1987-05-11 1988-05-25 Ici America Inc Heterocyclic ketones
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
ATE246708T1 (de) 1994-06-02 2003-08-15 Aventis Pharma Inc Elatase-inhibitoren
JPH0820597A (ja) 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6022861A (en) * 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6211154B1 (en) * 1995-06-07 2001-04-03 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5827860A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5523308A (en) * 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
TW523513B (en) 1996-03-01 2003-03-11 Akzo Nobel Nv Serine protease inhibitors
NZ332740A (en) 1996-06-18 2000-05-26 Warner Lambert Co heterocyclically substituted carbamate or sulphonamide derivatives
IL121474A0 (en) 1996-08-23 1998-02-08 Akzo Nobel Nv Thrombin inhibitors
DE69709671T2 (de) * 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
JP3220169B2 (ja) 1996-12-06 2001-10-22 コーテック インコーポレーテッド セリンプロテアーゼ阻害剤
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
JP2001524117A (ja) 1997-05-02 2001-11-27 アクゾ・ノベル・エヌ・ベー セリンプロテアーゼ阻害剤
JP4452401B2 (ja) 1997-08-11 2010-04-21 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎ウイルス阻害ペプチドアナログ
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
EP1114822A3 (en) 1998-06-03 2002-11-13 Cortech Inc. Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
CN1353701A (zh) * 1999-01-27 2002-06-12 奥索-麦克尼尔药品公司 用作类胰蛋白酶抑制剂的肽基杂环酮类化合物
JP2000256396A (ja) * 1999-03-03 2000-09-19 Dainippon Pharmaceut Co Ltd 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
GB9923710D0 (en) 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
CA2390349A1 (en) 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
ATE461207T1 (de) * 2000-07-21 2010-04-15 Schering Corp Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus
JP2002138048A (ja) * 2000-08-25 2002-05-14 Dainippon Pharmaceut Co Ltd 複素環式化合物からなる医薬
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
ES2279879T3 (es) 2001-07-11 2007-09-01 Vertex Pharmaceuticals Incorporated Inhibidores biciclicos puente de la serina proteasa.
AU2003248360A1 (en) 2002-02-08 2003-09-09 Idun Pharmaceuticals, Inc. (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US7205384B2 (en) 2003-08-05 2007-04-17 Ortho-Mcneil Pharmaceutical Inc. Process for preparing peptidyl heterocyclic ketone derivatives
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
AU2004282148A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CA2549167A1 (en) 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
US20050222383A1 (en) 2004-02-05 2005-10-06 Irm Llc Prostasin substrates and inhibitors
WO2005087721A2 (en) 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
JP5032299B2 (ja) 2004-03-24 2012-09-26 シャイア・オーファン・セラピーズ・ゲーエムベーハー 血管形成を阻害する新規化合物及びその使用
EP1773868B1 (en) * 2004-05-20 2009-07-15 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
WO2006006644A1 (ja) 2004-07-14 2006-01-19 Kyowa Hakko Kogyo Co., Ltd. 複素環式化合物
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
CA2651043A1 (en) * 2006-05-23 2007-12-06 David C. Tully Compounds and compositions as channel activating protease inhibitors
KR101069051B1 (ko) * 2006-05-23 2011-09-29 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
DK2104535T3 (da) * 2007-01-10 2011-04-04 Irm Llc Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
AU2008214214B2 (en) * 2007-02-09 2011-09-15 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2117537A1 (en) 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors

Also Published As

Publication number Publication date
CA2677487A1 (en) 2008-08-14
EA200901083A1 (ru) 2010-02-26
AU2008214217B2 (en) 2011-10-13
EA016327B1 (ru) 2012-04-30
WO2008097676A1 (en) 2008-08-14
CN101600428A (zh) 2009-12-09
EP2117537A1 (en) 2009-11-18
AU2008214217A1 (en) 2008-08-14
JP2010518099A (ja) 2010-05-27
KR20090108131A (ko) 2009-10-14
US8293915B2 (en) 2012-10-23
US20100056756A1 (en) 2010-03-04
BRPI0807483A2 (pt) 2014-05-13

Similar Documents

Publication Publication Date Title
TN2009000294A1 (en) Compounds and compositions as channel activating protease inhibitors
MX2009008493A (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
MX2009008518A (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
WO2007137080A3 (en) Compounds and compositions as channel activating protease inhibitors
WO2007079096A3 (en) Protease inhibition
SE0201980D0 (sv) Novel compounds
IL176848A (en) Compounds of 3– hcv ns Serine Protease, Pharmaceutical Preparations Containing and Using Them
TN2009000520A1 (en) Kallikrein 7 modulators
MX2010008523A (es) Inhibidores macrociclicos de serina proteasa.
SE0201976D0 (sv) Novel compounds
IL183308A0 (en) Cathepsin cysteine protease inhibitors
UA74372C2 (uk) Інгібітори серинових протеаз, фармацевтична композиція на їх основі
IL193252A0 (en) N-hydroxyacrylamide compounds
GB0222722D0 (en) Enzyme-sensitive therapeutic wound dressings
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
NO20075370L (no) Alfa-ketoamidforbindelser som cysteinproteaseinhibitorer
SE0201977D0 (sv) Novel compounds
UY30629A1 (es) Nuevo péptido de actinomadura namibiensis
DK1292673T3 (da) Trombomodulinanaloger til farmaceutisk anvendelse
SE0203712D0 (sv) Novel compounds
MX2008002493A (es) Composicion farmaceutica solida que comprende 1-(4-cloro-anilino)-4-(4-piridil-metil)-ftalazina y un modificador del ph.
WO2005063742A3 (en) Amidino compounds as cysteine protease inhibitors
SI1729794T1 (sl) Farmacevtski pripravek, ki vsebuje sulfobetain, ki nima lastnosti detergenta
UA95502C2 (ru) Соединения и композиция как ингибиторы активирующей каналы протеазы
TW200510436A (en) Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss

Legal Events

Date Code Title Description
FA Abandonment or withdrawal